



SolAeroMed Inc.  
120-4838 Richard Road SW  
Calgary, AB T3E 6L1 Canada  
[www.solaeromed.com](http://www.solaeromed.com)

SolAeroMed Shareholder Newsletter June 27 2018

Hello SolAeroMed shareholders

I write to provide an update on evolving developments at SolAeroMed (SAMi) and share news of recent events.

1. SAMi continues to have promising discussions with potential partners in relation to our drug and device technologies. Discussions are ongoing with parties in the USA and China. Confidentiality dictates few details can be released, though I am optimistic these discussions will result in material developments.
2. The ICU case study we reported to shareholders continues to do well. We have since presented this case study the ATS respiratory conference in San Diego and received great feedback. [Link to clinical poster](#). We expect future dissemination through publication will generate further interest in our S1226 drug technology.
3. Based on the success of this ICU case study, SAMi management has approached Health Canada to explore regulatory approval of S1226 for limited use within the ICU setting. Health Canada is reviewing the submitted data.
4. We have completed a \$150,000 device development program in collaboration with Calgary based SAIT. This program has advanced design aspects of our S1226 portable device and, amongst other outcomes, has provided SAMi with detailed rapid prototypes of an evolved S1226 portable device, which builds on the initial device engineering provided by Melbourne based Hydrix. [Link to design](#).
5. We continue to advance our patent portfolio, by expanding international patent filings for our S1226 portable delivery device as well as formally responding to challenges from S1229 patent examiners.

As CEO of SolAeroMed, I can confirm our SolAeroMed drug technologies are generating attention. However, we remain in a difficult point in our business development history as we strive to transition beyond our small private company, funded by 'friends and family'. This difficulty is shared by many 'early phase' biotech companies as they transition through regulatory approval. SolAeroMed is somewhat disadvantaged in our oil and gas centric Alberta location which is not known for biotech innovation. However, we believe any disadvantage is more than offset by a lead S1226 drug which has strong patents, a great safety profile, relatively low development costs; advanced clinical data demonstrating safety and efficacy as well as motivated founding management, responsible Board oversight, and a very low burn rate which allow us to efficiently eek out available funds. As we negotiate and advance partner discussions, SolAeroMed management continues to advance our R&D, maintain our patent portfolio, and promote our technologies as best we are able.

We will be hosting our 2018 AGM in Calgary this fall. In due course, we will announce AGM details including date and venue by email and [www](#)

Please contact me directly to discuss any aspect of our evolving drug technology, development plans, investment or management.

John Dennis, PhD  
CEO, SolAeroMed

[jdennis@solaeromed.com](mailto:jdennis@solaeromed.com)